Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis
- 1Department of Cerebrovascular Disease, Affiliated Hospital of Zunyi Medical University, Guizhou, China
- 2College of Life Sciences, Wuhan University, Wuhan, China
A Corrigendum on
Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis
by Zhang, Q., Zhong, H., Fan, Y., Liu, Q., Song, J., Yao, S., et al. (2020). Front. Bioeng. Biotechnol. 8:592. doi: 10.3389/fbioe.2020.00592
In the published article, there was an error in affiliation 1. Instead of “Department of Cerebrovascular Disease, The First Affiliated Hospital of Zunyi Medical University, Guizhou, China”, it should be “Department of Cerebrovascular Disease, Affiliated Hospital of Zunyi Medical University, Guizhou, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: CD96, glioma, immune checkpoint, prognosis, immunotherapy
Citation: Zhang Q, Zhong H, Fan Y, Liu Q, Song J, Yao S and Cao F (2020) Corrigendum: Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis. Front. Bioeng. Biotechnol. 8:599544. doi: 10.3389/fbioe.2020.599544
Received: 27 August 2020; Accepted: 03 September 2020;
Published: 23 October 2020.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2020 Zhang, Zhong, Fan, Liu, Song, Yao and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shengtao Yao, YST@zmu.edu.cn; Fang Cao, caof@zmu.edu.cn
†These authors have contributed equally to this work and share first authorship